Literature DB >> 16278769

Ziprasidone mesylate (Geodon for injection): the first injectable atypical antipsychotic medication.

Valerie Sheehan1.   

Abstract

Entities:  

Year:  2003        PMID: 16278769      PMCID: PMC1214571          DOI: 10.1080/08998280.2003.11927949

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


× No keyword cloud information.
  8 in total

1.  Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult.

Authors: 
Journal:  Am J Health Syst Pharm       Date:  2002-01-15       Impact factor: 2.637

2.  Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients.

Authors:  M D Lesem; J M Zajecka; R H Swift; K R Reeves; E P Harrigan
Journal:  J Clin Psychiatry       Date:  2001-01       Impact factor: 4.384

3.  Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group.

Authors:  S Brook; J V Lucey; K P Gunn
Journal:  J Clin Psychiatry       Date:  2000-12       Impact factor: 4.384

4.  Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial.

Authors:  D G Daniel; S G Potkin; K R Reeves; R H Swift; E P Harrigan
Journal:  Psychopharmacology (Berl)       Date:  2001-05       Impact factor: 4.530

Review 5.  Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.

Authors:  A H Glassman; J T Bigger
Journal:  Am J Psychiatry       Date:  2001-11       Impact factor: 18.112

Review 6.  Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.

Authors:  Nishan S Gunasekara; Caroline M Spencer; Gillian M Keating
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 7.  Ziprasidone: the fifth atypical antipsychotic.

Authors:  Charles F Caley; Chandra K Cooper
Journal:  Ann Pharmacother       Date:  2002-05       Impact factor: 3.154

Review 8.  Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.

Authors:  Peter M Haddad; Ian M Anderson
Journal:  Drugs       Date:  2002       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.